Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

Sung Eun Sim, Carl Risinger, Eleni Aklillu et al. · Clinical Pharmacology & Therapeutics · 2006 · 721 citations

Impact of the Ultrarapid CYP2C19*17 Allele on Serum Concentration of Escitalopram in Psychiatric Patients

Ida Rudberg, B. Urbanczyk Mohebi, Monica Hermann et al. · Clinical Pharmacology & Therapeutics · 2007 · 231 citations

Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype

Ming Chang, Marja-Liisa Dahl, Gunnel Tybring et al. · Pharmacogenetics · 1995 · 203 citations

Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram.

Lisa L. von Moltke, David J. Greenblatt, Gina M. Giancarlo et al. · PubMed · 2001 · 199 citations

Microm Quinidine, Secondary Metabolite, Pharmacotherapy +17

Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole

Tommy Andersson, C. Cederberg, Gunilla Edvardsson et al. · Clinical Pharmacology & Therapeutics · 1990 · 165 citations